Seeking Alpha

An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was...

An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was safe and effective at treating COPD. The agency's pulmonary-allergy advisory committee is still reviewing the drug and has to vote on whether the product should be marketed, but today's positive vote makes it likely the panel will vote affirmatively to support approval. Shares remain halted.
Comments (1)
  • b.holden
    , contributor
    Comments (39) | Send Message
     
    Soon next in line
    THLD
    (I hope!)
    Lars
    17 Apr 2013, 08:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector